Craniomaxillofacial and Upper Extremity Allotransplantation | NCT04057638 | Trialant
NCT04057638
Sponsor
NYU Langone Health
Status
Recruiting
Last Update Posted
Dec 16, 2025Actual
Enrollment
10Estimated
Phase
Not Applicable
Conditions
Face Injuries
Hand Injuries
Craniofacial Injuries
Upper Extremity Injuries
Facial Injuries
Facial Deformity
Interventions
Combined Craniomaxillofacial and Upper Extremity Allotransplantation
Countries
United States
Protocol Section
Identification Module
NCT ID
Results Section
No data available
No data is available for this block.
Annotation Section
No data available
No data is available for this block.
Document Section
No data available
No data is available for this block.
Derived Section
Miscellaneous Info Module
Version Holder
NCT04057638
Obsolete or Duplicate NCT IDs
Not provided
Organization Study
s19-00621
Secondary IDs
Not provided
Brief Title
Craniomaxillofacial and Upper Extremity Allotransplantation
Official Title
Combined Craniomaxillofacial and Upper Extremity Allotransplantation
Acronym
Not provided
Organization
NYU Langone HealthOTHER
Status Module
Record Verification Date
Dec 2025
Overall Recruitment Status or Expanded Access Status
Recruiting
Last Known Status
Not provided
Delayed Posting
Not provided
Why Stopped
Not provided
Expanded Access Info
No
Start Date
Jun 17, 2019Actual
Primary Completion Date
Jan 1, 2026Estimated
Completion Date
Jan 1, 2026Estimated
First Submitted Date
Aug 6, 2019
First Submission Date that Met QC Criteria
Aug 13, 2019
First Posted Date
Aug 15, 2019Actual
Results Waived
Not provided
Results First Submitted Date
Not provided
Results First Submitted that Met QC Criteria
Not provided
Results First Posted Date
Not provided
Certification/Extension (aka Delayed Results) First Submitted Date
Not provided
Certification/Extension First Submitted that Passed QC Review
Not provided
Certification/Extension First Posted Date
Not provided
Last Update Submitted Date
Dec 8, 2025
Last Update Posted Date
Dec 16, 2025Actual
Sponsor/Collaborators Module
Responsible Party, by Official Title
Sponsor
Lead Sponsor
NYU Langone HealthOTHER
Collaborators
Not provided
Oversight Module
Has Data Monitoring Committee (DMC)
Yes
Is FDA Regulated Drug
No
Is FDA Regulated Device
No
Is Unapproved Device
Not provided
Pediatric Postmarket Surveillance of a Device Product
Not provided
Product Exported from US
Not provided
FDAAA801 Violation
Not provided
Description Module
Brief Summary
The purpose of this study is to evaluate functional and aesthetic outcomes of combined facial and upper extremity composite tissue allografts on patients who have not achieved functional and aesthetic outcomes with conventional reconstructive surgical strategies and prosthetic devices.
Detailed Description
The purpose of this study is to see if an investigational surgery that transfers tissue from a non-living donor to a living individual will help restore greater function, appearance, and sensation to the face and upper extremity areas of individuals who have suffered injury to those areas. Upper extremity constitutes the part of the body including arm, forearm and hand. This procedure is called combined craniomaxillofacial and upper extremity allotransplantation or "combined face and upper extremity transplant".
This study will also collect data on how patients do during and after having a combined face and upper extremity transplant from a nonliving donor. Recovery and outcomes will be observed through clinical exams, x-rays, blood and tissue tests, and other associated evaluations at all follow up visits.
Participants are invited to take part in this research study who have suffered severe injury to the face and upper extremity and previous surgeries to repair the injury have not restored function, appearance, and sensation. Participants must have attempted a trial of prosthetics (artificial upper extremity), if at all possible.
Conditions Module
Conditions
Face Injuries
Hand Injuries
Craniofacial Injuries
Upper Extremity Injuries
Facial Injuries
Facial Deformity
Keywords
Transplants
Transplantation
Craniomaxillofacial Transplantation
Upper Extremity Transplantation
Vascularized Composite Allotransplantation (VCA)
Design Module
Study Type
Interventional
Number of References to an Expanded Access Study
Not provided
Expanded Access Types
Not provided
Patient Registry
Not provided
Target Follow-Up Duration
Not provided
Phases
Not Applicable
Interventional Study Design
Allocation
Biospecimen
No data available
No data is available for this block.
Enrollment
10Estimated
Arms/Interventions Module
Arm Groups
Label
Type
Description
Intervention Names
Treatment group
Experimental
There will only be the treatment group in this study, which undergoes microvascular VCA transplantation. There will be no randomization, placebo or control groups.
Procedure: Combined Craniomaxillofacial and Upper Extremity Allotransplantation
Interventions
Name
Type
Description
Arm Group Labels
Other Names
Combined Craniomaxillofacial and Upper Extremity Allotransplantation
Procedure
Combined Craniomaxillofacial and Upper Extremity Allotransplantation
Treatment group
Outcomes Module
Primary Outcomes
Measure
Description
Time Frame
Change in function of the transplanted facial segment
This will be measured using electromyogram (EMG)
Monthly for 6 months, every 6 months for 2 years, then annually up to year 5
Change in function of the transplanted facial segment
This will be measured using nerve conduction studies (NCS)
Monthly for 6 months, every 6 months for 2 years, then annually up to year 5
Change in function of the transplanted facial segment
This will be measured using computerized tomography angiogram (CTA)
Monthly for 6 months, every 6 months for 2 years, then annually up to year 5
Change in function of the transplanted facial segment
This will be measured using magnetic resonance imaging (MRI)
Monthly for 6 months, every 6 months for 2 years, then annually up to year 5
Change in function of the transplanted facial segment
This will be measured using vision exams
Monthly for 6 months, every 6 months for 2 years, then annually up to year 5
Change in function of the upper extremity transplant
This will be measured using pathology samples to check for rejection
Monthly for 6 months, every 6 months for 2 years, then annually up to year 5
Change in function of the upper extremity transplant
This will be measured using electromyogram (EMG)
Secondary Outcomes
Not provided
Other Outcomes
Not provided
Eligibility Module
Eligibility Criteria
Inclusion Criteria:
Signed and dated all required Institutional Review Board (IRB) approved consent forms.
Male or female recipient between the ages of 18-64 years. Recipients do not need to be of the same sex as the donor.
Facial composite tissue defect requiring facial transplantation as determined by the treating Plastic and Reconstructive Surgeon. Inclusive facial functional subunit tissue loss. Including but not limited to irreparable peri-oral, peri-orbital, and peri-nasal damage.
Missing part of one or both hands and forearms.
Must be HIV negative at the time of transplant.
Crossmatch is negative at the time of transplant.
Patient has been encouraged to seek a second opinion from a Plastic Surgeon with specialized focus in facial reconstruction.
Patient has been encouraged to seek a second opinion from a Plastic Surgeon with specialized focus in upper extremity reconstruction.
Willingness to participate in ongoing psychiatric, psychological and social work evaluations prior to and post-transplant surgery.
The subject is able to complete pre-transplant examination and screening procedures.
Patient has been approved by Patient Selection Committee for placement on the recipient waiting list.
The subject is willing to continue immunosuppression regimen as directed by treating physician.
Subject is willing and able to return to follow-up visits as described in treatment plan.
Subjects must have autogenous tissue options available for reconstruction in event of graft failure.
Normal glomerular filtration rate (GFR) >60.
Negative pregnancy test within 48hrs of transplant for women of childbearing age and who agree to use a reliable form of contraception for one year following transplant.
Exclusion Criteria:
Uncontrolled infection or severe concomitant diseases which would exclude the recipient from transplantation
Serious co-morbidities
Positive serology for HIV; Hepatitis B Antigen
Active malignancy within 5 years with the exclusion of non-melanoma
Substance abuse disorders not currently under control (as determined by the Michigan Alcohol Screening Test - see Appendix N.1: Subjects with a score of 3 or more will be excluded)
Body Dysmorphic disorder (see Appendix N.2 for screening tool). Less severe psychiatric conditions are addressed on a case by case basis
Active Severe Psychiatric Illness
Cognitive limitations affecting the patient's ability to provide informed consent
Recent history of medical non-adherence
Unstable social situation as evidence by lack of stable housing and/or lack of a supportive significant other.
Recent history of medical non-adherence.
Lack of stable housing and/or supportive significant other/caregiver throughout all phases of the study
Currently active smoker within 1 year
Subjects with any cognitive deficits related to a traumatic brain injury (TBI) and or any organic neurological disorders
Any other psychological status that would hinder the success or safety of the transplantation.
Level of amputation proximal to mid-humerus: some presence of proximal muscles is required to motor a functioning hand.
Congenital Abnormalities: co-existent absence/atrophy/agenesis of any tissue may affect post-transplant results
History of amputation of less than six months: subject must be allowed to attempt prosthetic use prior to hand transplantation. This can be waived in cases where the recipient requires amputation/revision of the transplant site at the time of transplantation. However, if at all possible, it is highly encouraged that the patient has ruled out prosthetics as an alternative to transplantation.
Blindness: blind amputees may be poor candidates because sensory return in the hand may not provide sufficient protective sensation
Pregnancy
Accepts Healthy Volunteers
No
Sex
All
Sex/Gender Based
Not provided
Sex/Gender Description
Not provided
Minimum Age
18 Years
Maximum Age
64 Years
Standard Ages
Adult
Study Population
Not provided
Sampling Method
Not provided
Contacts/Locations Module
Central Contacts
Name
Role
Phone
Extension
Email
Thomas Calahan, BA
Contact
(929) 455-5826
Thomas.Calahan@nyulangone.org
Overall Officials
Name
Affiliation
Role
Eduardo Rodriguez, MD, DDS
NYU Langone Medical Center
Principal Investigator
Locations
Facility
Status
City
State
ZIP
Country
Contacts
NYU Langone Health
Recruiting
New York
New York
10017
United States
References Module
No data available
No data is available for this block.
IPD Sharing Statement Module
No data available
No data is available for this block.
Jul 10, 2026
Removed Countries
Not provided
Submission Tracking
No data available
No data is available for this block.
Condition Browse Module
MeSH Terms
ID
Term
D005151
Facial Injuries
D006230
Hand Injuries
Ancestor Terms
ID
Term
D006259
Craniocerebral Trauma
D020196
Trauma, Nervous System
D009422
Nervous System Diseases
D014947
Wounds and Injuries
Browse Leaves
Not provided
Browse Branches
Not provided
Intervention Browse Module
No data available
No data is available for this block.
N/A
Intervention Model
Single Group Assignment
Intervention Model Description
This is a prospective longitudinal observational analysis of functional and aesthetic outcomes after treatment of severe facial defects and upper extremity injuries with microvascular composite tissue allotransplantation. There will only be the treatment group in this study, which undergoes microvascular VCA transplantation. There will be no randomization, placebo or control groups.
Primary Purpose
Treatment
Observational Model
Not provided
Time Perspective
Not provided
Masking Info
Masking
None (Open Label)
Masking Description
Not provided
Who Masked
Not provided
Monthly for 6 months, every 6 months for 2 years, then annually up to year 5
Change in function of the upper extremity transplant
This will be measured using nerve conduction studies (NCS)
Monthly for 6 months, every 6 months for 2 years, then annually up to year 5
Change in function of the upper extremity transplant
This will be measured using computerized tomography angiogram (CTA)
Monthly for 6 months, every 6 months for 2 years, then annually up to year 5
Change in function of the upper extremity transplant
This will be measured using magnetic resonance imaging (MRI)
Monthly for 6 months, every 6 months for 2 years, then annually up to year 5
Change in appearance of the transplanted facial segment
This will be measured using photography
Monthly for 6 months, every 6 months for 2 years, then annually up to year 5
Change in appearance of the upper extremity transplant
This will be measured using photography
Monthly for 6 months, every 6 months for 2 years, then annually up to year 5